Role of the angiogenic components, VEGFA, FGF2, OPN and RHOC, in urothelial cell carcinoma of the urinary bladder

Zaravinos,Apostolos; Volanis,Dimitrios; Lambrou,George  I.; Delakas,Dimitris; Spandidos,Demetrios  A.

doi:10.3892/or.2012.1948

Role of the angiogenic components, VEGFA, FGF2, OPN and RHOC, in urothelial cell carcinoma of the urinary bladder

Authors:
- Apostolos Zaravinos
- Dimitrios Volanis
- George I. Lambrou
- Dimitris Delakas
- Demetrios A. Spandidos
View Affiliations

Affiliations: Laboratory of Virology, Medical School, University of Crete, 71110 Heraklion, Crete, Greece, First Department of Pediatrics, Choremeio Research Laboratory, University of Athens, 11527 Athens, Greece, Department of Urology, Asklipieio General Hospital, 16673 Voula, Athens, Greece
Published online on: August 3, 2012 https://doi.org/10.3892/or.2012.1948
Pages: 1159-1166
Copyright: © Zaravinos et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The objective of this study was to analyze the expression profile of the angiogenic components, vascular endothelial growth factor-A (VEGFA), basic fibroblast growth factor-2 (FGF2), osteopontin (OPN) and ras homolog gene family, member C (RHOC), in urothelial cell carcinoma (UCC) of the urinary bladder and to examine their role as candidate diagnostic biomarkers. Using qPCR, 77 samples of UCC of the urinary bladder and 77 matched tumor-associated normal samples were investigated to determine the expression of the four angiogenic components. The correlation between gene expression, patient survival and pathological features of the tumors was also examined. The VEGFA and OPN transcript levels were greater in the bladder cancer tissue than in the normal urothelium (P<0.001). Patients with higher VEGFA mRNA levels showed a tendency towards shorter cancer-specific survival. OPN levels showed a gradual increase, the lowest levels being found in non-invasive carcinoma and the highest in muscle invasive tumors. Elevated OPN levels indicated poor prognosis in connection with advanced disease stage (P<0.001). Both superficially invasive and muscle invasive tumors had significantly higher FGF2 levels compared to the control tissues (P=0.018 and P=0.050, respectively). Moreover, FGF2 was significantly higher in the metastatic vs. the non-metastatic tumors (P=0.0097). FGF2 levels exhibited a trend towards a correlation with worse patient survival. RHOC mRNA levels were higher in muscle invasive compared to superficially invasive tumors, as well as in grade III vs. grade I/II tumors. Furthermore, we detected worse overall survival for patients with high RHOC expression levels. VEGFA and FGF2 exhibited the best linear combination in the ROC curves for specificity and sensitivity. Thus, VEGFA and FGF2 may serve as candidate biomarkers for diagnostic purposes. Higher OPN expression may be used as a potential biomarker to predict patient survival relative to advanced tumor stage. However, further studies are required to investigate its role in urinary bladder carcinogenesis.

View Figures

View References

1	Folkman J and Shing Y: Angiogenesis. J Biol Chem. 267:10931–10934. 1992.
2	Jayet C, Deperthes D and Leisinger HJ: Angiogenesis and bladder cancer: trendy prognostic factor or new therapeutic target? Ann Urol (Paris). 36:258–263. 2002.(Article in French).
3	Bochner BH, Cote RJ, Weidner N, et al: Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst. 87:1603–1612. 1995. View Article : Google Scholar : PubMed/NCBI
4	Donmez G, Sullu Y, Baris S, et al: Vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and thrombospondin-1 (TSP-1) expression in urothelial carcinomas. Pathol Res Pract. 205:854–857. 2009. View Article : Google Scholar : PubMed/NCBI
5	Pignot G, Bieche I, Vacher S, et al: Large-scale real-time reverse transcription-PCR approach of angiogenic pathways in human transitional cell carcinoma of the bladder: identification of VEGFA as a major independent prognostic marker. Eur Urol. 56:678–688. 2009. View Article : Google Scholar
6	Chikazawa M, Inoue K, Fukata S, Karashima T and Shuin T: Expression of angiogenesis-related genes regulates different steps in the process of tumor growth and metastasis in human urothelial cell carcinoma of the urinary bladder. Pathobiology. 75:335–345. 2008. View Article : Google Scholar : PubMed/NCBI
7	El-Tanani MK: Role of osteopontin in cellular signaling and metastatic phenotype. Front Biosci. 13:4276–4284. 2008. View Article : Google Scholar : PubMed/NCBI
8	Rittling SR and Chambers AF: Role of osteopontin in tumour progression. Br J Cancer. 90:1877–1881. 2004. View Article : Google Scholar : PubMed/NCBI
9	Ang C, Chambers AF, Tuck AB, Winquist E and Izawa JI: Plasma osteopontin levels are predictive of disease stage in patients with transitional cell carcinoma of the bladder. BJU Int. 96:803–805. 2005. View Article : Google Scholar : PubMed/NCBI
10	Zaravinos A, Lambrou GI, Volanis D, Delakas D and Spandidos DA: Spotlight on differentially expressed genes in urinary bladder cancer. PloS One. 6:e182552011. View Article : Google Scholar : PubMed/NCBI
11	Wang W, Wu F, Fang F, Tao Y and Yang L: RhoC is essential for angiogenesis induced by hepatocellular carcinoma cells via regulation of endothelial cell organization. Cancer Sci. 99:2012–2018. 2008.PubMed/NCBI
12	Fritz G, Just I and Kaina B: Rho GTPases are over-expressed in human tumors. Int J Cancer. 81:682–687. 1999. View Article : Google Scholar : PubMed/NCBI
13	Kamai T, Tsujii T, Arai K, et al: Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res. 9:2632–2641. 2003.PubMed/NCBI
14	Volanis D, Zaravinos A, Kadiyska T, Delakas D, Zoumpourlis V and Spandidos DA: Expression profile of Rho kinases in urinary bladder cancer. J BUON. 16:511–521. 2011.PubMed/NCBI
15	Zaravinos A, Chatziioannou M, Lambrou GI, Boulalas I, Delakas D and Spandidos DA: Implication of RAF and RKIP genes in urinary bladder cancer. Pathol Oncol Res. 17:181–190. 2011. View Article : Google Scholar : PubMed/NCBI
16	Boulalas I, Zaravinos A, Delakas D and Spandidos DA: Mutational analysis of the BRAF gene in transitional cell carcinoma of the bladder. Int J Biol Markers. 24:17–21. 2009.PubMed/NCBI
17	Zaravinos A, Lambrou GI, Boulalas I, Delakas D and Spandidos DA: Identification of common differentially expressed genes in urinary bladder cancer. PloS One. 6:e181352011. View Article : Google Scholar : PubMed/NCBI
18	Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1:27–31. 1995. View Article : Google Scholar : PubMed/NCBI
19	Ke HL, Chang LL, Yang SF, et al: Osteopontin overexpression predicts poor prognosis of upper urinary tract urothelial carcinoma. Urol Oncol. 29:703–709. 2011. View Article : Google Scholar : PubMed/NCBI
20	Inoue K, Slaton JW, Karashima T, et al: The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res. 6:4866–4873. 2000.
21	Yang S, Wu X, Luo C, Pan C and Pu J: Expression and clinical significance of hepaCAM and VEGF in urothelial carcinoma. World J Urol. 28:473–478. 2010. View Article : Google Scholar : PubMed/NCBI
22	Shariat SF, Youssef RF, Gupta A, et al: Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. J Urol. 183:1744–1750. 2010. View Article : Google Scholar : PubMed/NCBI
23	Zachos I, Konstantinopoulos PA, Tzortzis V, et al: Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise. Expert Opin Investig Drugs. 19:875–887. 2010. View Article : Google Scholar : PubMed/NCBI
24	Chakraborty G, Jain S and Kundu GC: Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res. 68:152–161. 2008. View Article : Google Scholar
25	Marzioni D, Lorenzi T, Mazzucchelli R, et al: Expression of basic fibroblast growth factor, its receptors and syndecans in bladder cancer. Int J Immunopathol Pharmacol. 22:627–638. 2009.PubMed/NCBI
26	Gan Y, Wientjes MG and Au JL: Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors. Pharm Res. 23:1324–1331. 2006. View Article : Google Scholar : PubMed/NCBI
27	Gravas S, Bosinakou I, Kehayas P and Giannopoulos A: Urinary basic fibroblast growth factor in bladder cancer patients. Histopathological correlation and clinical potential. Urol Int. 73:173–177. 2004. View Article : Google Scholar
28	Stoletov K, Montel V, Lester RD, Gonias SL and Klemke R: High-resolution imaging of the dynamic tumor cell vascular interface in transparent zebrafish. Proc Natl Acad Sci USA. 104:17406–17411. 2007. View Article : Google Scholar : PubMed/NCBI
29	Abe H, Kamai T, Tsujii T, et al: Possible role of the RhoC/ROCK pathway in progression of clear cell renal cell carcinoma. Biomed Res. 29:155–161. 2008. View Article : Google Scholar : PubMed/NCBI
30	Horiuchi A, Imai T, Wang C, et al: Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Lab Invest. 83:861–870. 2003. View Article : Google Scholar : PubMed/NCBI